Davis's Drug Guide
daridorexant
General
Pronunciation:
dar-i-doe-rex-ant
Trade Name(s)
- Quviviq
Ther. Class.
Pharm. Class.
orexin receptor antagonists
Controlled Substance Schedule: IV
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Daridorexant." Davis's Drug Guide, 18th ed., F.A. Davis Company, 2023. Medicine Central, im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110939/1/daridorexant.
Vallerand AHA, Sanoski CAC, Quiring CC. Daridorexant. Davis's Drug Guide. F.A. Davis Company; 2023. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110939/1/daridorexant. Accessed April 27, 2024.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Daridorexant. In Davis's Drug Guide (18th ed.). F.A. Davis Company. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110939/1/daridorexant
Vallerand AHA, Sanoski CAC, Quiring CC. Daridorexant [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2023. [cited 2024 April 27]. Available from: https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110939/1/daridorexant.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - daridorexant
ID - 110939
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110939/1/daridorexant
PB - F.A. Davis Company
ET - 18
DB - Medicine Central
DP - Unbound Medicine
ER -
